Suggested remit: To evaluate the benefits and costs of setmelanotide within its marketing authorisation for treating obesity caused by leptin receptor (LEPR) deficiency or pro-opiomelanocortin (POMC) deficiency for national commissioning by NHS England.
 
Status In progress
Decision Selected
Process HST
ID number 3764

Provisional Schedule

Expected publication 20 July 2022

Project Team

Project lead Daniel Davies

Email enquiries

External Assessment Group Peninsula Technology Assessment Group (PenTAG), University of Exeter

Stakeholders

Companies sponsors Rhythm Pharmaceuticals (setmelanotide)
Others NHS England
  Department of Health and Social Care
  Welsh Government
Patient carer groups None
Professional groups Royal College of Paediatrics & Child Health
  Royal College of Physicians
Associated public health groups None
Comparator companies GlaxoSmithKline Consumer Healthcare (orlistat)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups None

Timeline

Key events during the development of the guidance:

Date Update
03 June 2022 - 17 June 2022 Final evaluation determination: 3764
13 April 2022 Committee meeting: 2
31 January 2022 - 21 February 2022 Evaluation consultation
09 December 2021 Committee meeting: 1
10 May 2021 Invitation to participate
07 May 2021 In progress. In progress
31 July 2020 (14:00) Scoping workshop (Manchester)
08 June 2020 - 06 July 2020 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual